Subscription Required

Only paid subscribers to Radar on Specialty Pharmacy can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Radar on Specialty Pharmacy receive

  • 12 monthly issues packed with strategic information on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest grouped for convenient reading, and
    • Regular postings from your editor.
View a sample and get more information
April 2018

Recent Stories

From Radar on Specialty Pharmacy - CVS Health Corp. recently unveiled an initiative aimed at improving the management of chronic kidney disease (CKD), a costly condition that affects millions in the United States. The multipronged program incorporates, among other things, a focus on early disease identification and patient education, as well as a comprehensive home dialysis program that includes a clinical trial for a home hemodialysis device that CVS Health plans to submit to the FDA for market clearance. Read more

While there is no cure for the autoimmune condition psoriasis, various therapies… Read more

As the battle over rebates for specialty drugs continues, one health plan… Read more

Hereditary angioedema (HAE) is a rare but potentially fatal condition. It’s also… Read more

From the Editor

Welcome to Your Radar on Specialty Pharmacy Subscriber Website

Exclusively for subscribers to Radar on Specialty Pharmacy (formerly Specialty Pharmacy News), this website is your source for PDFs of back issues, archives of articles and data, and more!

Please e-mail me with comments on the latest issue, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

January 10, 2018
Specialty Pharmacy News is about to become Radar on Specialty Pharmacy

With the February issue of SPN, we will adopt a new publication name: Radar on Specialty Pharmacy. While our focus is still squarely on providing strategies and analysis for managing high-cost specialty products, our new name signals a renewed commitment to in-depth, forward-looking coverage. Every issue will bring incisive coverage of the companies, people, catalysts and trends that shape the pharma industry today and in the future.

Radar on Specialty Pharmacy will join our other newly named publications: Radar on Medicare Advantage (formerly Medicare Advantage News) and Radar on Drug Benefits (formerly Drug Benefit News), available alongside Health Plan Weekly and Health Business Daily. Visit the AISHealth Marketplace for more information about our publications.

November 16, 2017
FDA Begins Implementing Naming Guidance

The FDA has started adding 4-letter suffixes to non-biosimilar biologics per its January final guidance: Mepsevii (vestronidase alfa-vjbk) and Hemlibra (emicizumab-kxwh)

August 30, 2017
First Gene Therapy Gets FDA Approval

FDA approves first gene therapy in U.S., Novartis’ CAR-T drug Kymriah, for treatment of people up to 25 years old with B-cell precursor acute lymphoblastic leukemia that is refractory or has relapsed at least twice http://tinyurl.com/y8xku8ol

It's quick and easy to sign up for FREE access to AISHealth.com!

Why do I need to register?